Immuno‐Packed T‐Cell‐Fusogenic Liposome Empowers Adoptive T Cell Therapy for Solid Tumor Treatment

PPA peptide presentation enables T cells to overcome tumor cells' immune tolerance through PD-L1 checkpoint blockade. In a murine solid tumor model, IMPACTFUL-engineered T cells infiltrate tumors more effectively, resist exhaustion, and induce a more pro-inflammatory TME, leading to significantly suppressed tumor growth compared to unmodified T cells. Together, IMPACTFUL can empower adoptive T cell therapy by endowing T cells with multiple complementary functions in a single step. This approach offers a versatile platform to improve the therapeutic outcomes of T cell therapies against solid tumors and can accelerate their translation to clinical settings.